In accordance with one or more embodiments, the present invention provides pharmaceutical compositions and methods for specific cytotoxic therapy, including, but not limited to, specific non-thermal killing of targeted cells, for example, cancer cells or stem cells, by labeling, binding or introducing into the cytoplasm of the cells, one or more magnetic nanoparticles, such as superparamagnetic iron oxide (SPIO) nanoparticles for example, followed by exposing the cells to oscillating gradients of a magnetic field in the presence of strong static magnetic field such as B0 field generated by modern MRI systems. Specific labeling of cells can be achieved either by various means known in the art, including modifying the cell surface with targeted magnetic nanoparticles (wherein the magnetic nanoparticles are conjugated to one or more antibodies, peptides, or other high affinity ligands), or by loading the cells with nanoparticles internalized by endocytosis, pinocytosis, or through the use of standard cell transfection reagents and techniques. The static magnetic field as well as oscillating gradients can be produced by various known apparatus used to generate such fields, including, standard MRI systems. The methods provided herein make the technology applicable for clinical as well as in vitro use.Selon un ou plusieurs modes de réalisation, la présente invention concerne des compositions pharmaceutiques et des méthodes de thérapie cytotoxique spécifique, comprenant, mais sans y être limitées, lextermination non thermique spécifique de cellules ciblées, par exemple, de cellules cancéreuses ou de cellules souches, par marquage, liaison ou introduction dans le cytoplasme des cellules dune ou de plusieurs nanoparticules magnétiques, telles que, par exemple, des nanoparticules doxyde de fer superparamagnétique (SPIO), puis par exposition des cellules à des gradients doscillation dun champ magnétique en la présence dun puissant champ magnétique statique tel quun champ B0 gé
